Obesity and bipolar disorder: Synergistic neurotoxic effects?

Advances in Therapy

Volumn 30, Issue 11, 2013, Pages 987-1006

  Liu, Celina S ^a,b   Carvalho, André F ^c   Mansur, Rodrigo B ^a,b   McIntyre, Roger S ^a,b,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bipolar disorder; Body mass index; Central nervous system; Co occurrence; Comorbidity; Obesity; Psychiatry

Indexed keywords

ADIPOCYTOKINE; BRAIN DERIVED NEUROTROPHIC FACTOR; GLUCOCORTICOID; INSULIN; LITHIUM; MONOAMINE;

BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC DISEASE; COGNITIVE DEFECT; COMORBIDITY; CONCEPTUAL FRAMEWORK; DEPRESSION; DISEASE ASSOCIATION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MEDICAL RESEARCH; MONOAMINE METABOLISM; NEUROTOXICITY; NITROSATIVE STRESS; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROGNOSIS; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SUICIDAL BEHAVIOR; BODY MASS; FEMALE; INCIDENCE; MALE; METABOLISM; PHYSIOLOGIC MONITORING; SEVERITY OF ILLNESS INDEX;

BIPOLAR DISORDER; BODY MASS INDEX; CENTRAL NERVOUS SYSTEM DISEASES; COMORBIDITY; FEMALE; HUMANS; INCIDENCE; MALE; MONITORING, PHYSIOLOGIC; OBESITY; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 84890117197     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-013-0067-7     Document Type: Review

References (144)

1. Danaei G, Ding EL, Mozaffarian D, Taylor B, Rehm J, Murray CJ, et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med. 2009;6(4):e1000058.
2. Kwong JC, Campitelli MA, Rosella LC. Obesity and respiratory hospitalizations during influenza seasons in Ontario, Canada: a cohort study. Clin Infect Dis. 2011;53(5):413-21.
3. Vasiliadis HM, Lesage A, Adair C, Wang PS, Kessler RC. Do Canada and the United States differ in prevalence of depression and utilization of services? Psychiatr Serv. 2007;58(1):63-71.
4. Soczynska JK, Kennedy SH, Woldeyohannes HO, Liauw SS, Alsuwaidan M, Yim CY, et al. Mood disorders and obesity: understanding inflammation as a pathophysiological nexus. Neuromol Med. 2011;13(2):93-116.
5. McIntyre RS, Konarski JZ, Soczynska JK, Wilkins K, Panjwani G, Bouffard B, et al. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. Psychiatr Serv. 2006;57(8):1140-4.
6. Shah A, Shen N, El-Mallakh RS. Weight gain occurs after onset of bipolar illness in overweight bipolar patients. Ann Clin Psychiatry. 2006;18(4):239-41.
7. Wildes JE, Marcus MD, Fagiolini A. Obesity in patients with bipolar disorder: a biopsychosocial-behavioral model. J Clin Psychiatry. 2006;67(6):904-15.
8. Chen Y, Jiang Y, Mao Y. Association between obesity and depression in Canadians. J Womens Health (Larchmt). 2009;18(10):1687-92.
9. Jerrell JM, McIntyre RS, Tripathi A. A cohort study of the prevalence and impact of comorbid medical conditions in pediatric bipolar disorder. J Clin Psychiatry. 2010;71(11):1518-25.
10. Dickerson FB, Brown CH, Daumit GL, Fang L, Goldberg RW, Wohlheiter K, et al. Health status of individuals with serious mental illness. Schizophr Bull. 2006;32(3):584-9.
11. Calkin C, van de Velde C, Ruzickova M, Slaney C, Garnham J, Hajek T, et al. Can body mass index help predict outcome in patients with bipolar disorder? Bipolar Disord. 2009;11(6):650-6.
12. Wang PW, Sachs GS, Zarate CA, Marangell LB, Calabrese JR, Goldberg JF, et al. Overweight and obesity in bipolar disorders. J Psychiatr Res. 2006;40(8):762-4.
13. Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord. 2005;7(5):424-30.
14. Fagiolini A, Frank E, Houck PR, Mallinger AG, Swartz HA, Buysse DJ, et al. Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. J Clin Psychiatry. 2002;63(6):528-33.
15. Fagiolini A, Kupfer DJ, Houck PR, Novick DM, Frank E. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry. 2003;160(1):112-7.
16. Kemp DE, Gao K, Ganocy SJ, Caldes E, Feldman K, Chan PK, et al. Medical and substance use comorbidity in bipolar disorder. J Affect Disord. 2009;116(1-2):64-9.
17. Fagiolini A, Kupfer DJ, Rucci P, Scott JA, Novick DM, Frank E. Suicide attempts and ideation in patients with bipolar I disorder. J Clin Psychiatry. 2004;65(4):509-14.
18. Yim CY, Soczynska JK, Kennedy SH, Woldeyohannes HO, Brietzke E, McIntyre RS. The effect of overweight/obesity on cognitive function in euthymic individuals with bipolar disorder. Eur Psychiatry. 2012;27(3):223-8.
19. Ventimiglia J, Kalali AH, McIntyre R. Treatment of bipolar disorder. Psychiatry (Edgmont). 2009;6(10):12-4.
20. McIntyre RS, Kenna HA, Nguyen HT, Law CW, Sultan F, Woldeyohannes HO, et al. Brain volume abnormalities and neurocognitive deficits in diabetes mellitus: points of pathophysiological commonality with mood disorders? Adv Ther. 2010;27(2):63-80.
21. Bond DJ, Lang DJ, Noronha MM, Kunz M, Torres IJ, Su W, et al. The association of elevated body mass index with reduced brain volumes in first-episode mania. Biol Psychiatry. 2011;70(4):381-7.
22. Kuswanto CN, Sum MY, Yang GL, Nowinski WL, McIntyre RS, Sim K. Increased body mass index makes an impact on brain white-matter integrity in adults with remitted first-episode mania. Psychol Med. 2013;26:1-9.
23. Dutton GR, Bodell LP, Smith AR, Joiner TE. Examination of the relationship between obesity and suicidal ideation. Int J Obes (Lond). 2013;37(9):1282-6.
24. Leboyer M, Soreca I, Scott J, Frye M, Henry C, Tamouza R, et al. Can bipolar disorder be viewed as a multi-system inflammatory disease? J Affect Disord. 2012;141(1):1-10.
25. Barbosa IG, Rocha NP, de Miranda AS, Magalhaes PV, Huguet RB, de Souza LP, et al. Increased levels of adipokines in bipolar disorder. J Psychiatr Res. 2012;46(3):389-93.
26. Bruce-Keller AJ, Keller JN, Morrison CD. Obesity and vulnerability of the CNS. Biochim Biophys Acta. 2009;1792(5):395-400.
27. Tiwari HK, Patki A, Lieberman J, Stroup TS, Allison DB, Leibel RL, et al. Association of allelic variation in genes mediating aspects of energy homeostasis with weight gain during administration of antipsychotic drugs (CATIE Study). Front Genet. 2011;2:56.
28. Park HR, Park M, Choi J, Park KY, Chung HY, Lee J. A high-fat diet impairs neurogenesis: involvement of lipid peroxidation and brain-derived neurotrophic factor. Neurosci Lett. 2010;482(3):235-9.
29. Masopust J, Maly R, Valis M. Risk of venous thromboembolism during treatment with antipsychotic agents. Psychiatry Clin Neurosci. 2012;66(7):541-52.
30. McIntyre RS, Alsuwaidan M, Goldstein BI, Taylor VH, Schaffer A, Beaulieu S, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. Ann Clin Psychiatry. 2012;24(1):69-81.
31. McIntyre RS, Soczynska JK, Beyer JL, Woldeyohannes HO, Law CW, Miranda A, et al. Medical comorbidity in bipolar disorder: re-prioritizing unmet needs. Curr Opin Psychiatry. 2007;20(4):406-16.
32. Jerrell JM, McIntyre RS, Tripathi A. Childhood treatment with psychotropic medication and development of comorbid medical conditions in adolescent-onset bipolar disorder. Hum Psychopharmacol. 2011;26(7):451-9.
33. Goldstein TR, Goldstein BI, Mantz MB, Bailey B, Douaihy A. A brief motivational intervention for preventing medication-associated weight gain among youth with bipolar disorder: treatment development and case report. J Child Adolesc Psychopharmacol. 2011;21(3):275-80.
34. Lee NY, Kim SH, Cho B, Lee YJ, Chang JS, Kang UG, et al. Patients taking medications for bipolar disorder are more prone to metabolic syndrome than Korea's general population. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(7):1243-9.
35. Adler CM, Adams J, DelBello MP, Holland SK, Schmithorst V, Levine A, et al. Evidence of white matter pathology in bipolar disorder adolescents experiencing their first episode of mania: a diffusion tensor imaging study. Am J Psychiatry. 2006;163(2):322-4.
36. Beyer JL, Taylor WD, MacFall JR, Kuchibhatla M, Payne ME, Provenzale JM, et al. Cortical white matter microstructural abnormalities in bipolar disorder. Neuropsychopharmacology. 2005;30(12):2225-9.
37. Macritchie KA, Lloyd AJ, Bastin ME, Vasudev K, Gallagher P, Eyre R, et al. White matter microstructural abnormalities in euthymic bipolar disorder. Br J Psychiatry. 2010;196(1):52-8.
38. Yurgelun-Todd DA, Silveri MM, Gruber SA, Rohan ML, Pimentel PJ. White matter abnormalities observed in bipolar disorder: a diffusion tensor imaging study. Bipolar Disord. 2007;9(5):504-12.
39. Bruno S, Cercignani M, Ron MA. White matter abnormalities in bipolar disorder: a voxel-based diffusion tensor imaging study. Bipolar Disord. 2008;10(4):460-8.
40. Kafantaris V, Kingsley P, Ardekani B, Saito E, Lencz T, Lim K, et al. Lower orbital frontal white matter integrity in adolescents with bipolar I disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(1):79-86.
41. Mahon K, Wu J, Malhotra AK, Burdick KE, DeRosse P, Ardekani BA, et al. A voxel-based diffusion tensor imaging study of white matter in bipolar disorder. Neuropsychopharmacology. 2009;34(6):1590-600.
42. Sussmann JE, Lymer GK, McKirdy J, Moorhead TW, Munoz MS, Job D, et al. White matter abnormalities in bipolar disorder and schizophrenia detected using diffusion tensor magnetic resonance imaging. Bipolar Disord. 2009;11(1):11-8.
43. Wessa M, Houenou J, Leboyer M, Chanraud S, Poupon C, Martinot JL, et al. Microstructural white matter changes in euthymic bipolar patients: a whole-brain diffusion tensor imaging study. Bipolar Disord. 2009;11(5):504-14.
44. Barnea-Goraly N, Chang KD, Karchemskiy A, Howe ME, Reiss AL. Limbic and corpus callosum aberrations in adolescents with bipolar disorder: a tract-based spatial statistics analysis. Biol Psychiatry. 2009;66(3):238-44.
45. McIntosh AM, Munoz MS, Lymer GK, McKirdy J, Hall J, Sussmann JE, et al. White matter tractography in bipolar disorder and schizophrenia. Biol Psychiatry. 2008;64(12):1088-92.
46. Verstynen TD, Weinstein AM, Schneider WW, Jakicic JM, Rofey DL, Erickson KI. Increased body mass index is associated with a global and distributed decrease in white matter microstructural integrity. Psychosom Med. 2012;74(7):682-90.
47. Lochhead RA, Parsey RV, Oquendo MA, Mann JJ. Regional brain gray matter volume differences in patients with bipolar disorder as assessed by optimized voxel-based morphometry. Biol Psychiatry. 2004;55(12):1154-62.
48. Haznedar MM, Roversi F, Pallanti S, Baldini-Rossi N, Schnur DB, Licalzi EM, et al. Fronto-thalamo-striatal gray and white matter volumes and anisotropy of their connections in bipolar spectrum illnesses. Biol Psychiatry. 2005;57(7):733-42.
49. Taki Y, Kinomura S, Sato K, Inoue K, Goto R, Okada K, et al. Relationship between body mass index and gray matter volume in 1,428 healthy individuals. Obesity (Silver Spring). 2008;16(1):119-24.
50. Pannacciulli N, Del PA, Chen K, Le DS, Reiman EM, Tataranni PA. Brain abnormalities in human obesity: a voxel-based morphometric study. Neuroimage. 2006;31(4):1419-25.
51. Yokum S, Ng J, Stice E. Relation of regional gray and white matter volumes to current BMI and future increases in BMI: a prospective MRI study. Int J Obes (Lond). 2012;36(5):656-64.
52. Kilpatrick L, Cahill L. Amygdala modulation of parahippocampal and frontal regions during emotionally influenced memory storage. Neuroimage. 2003;20(4):2091-9.
53. Blumberg HP, Kaufman J, Martin A, Whiteman R, Zhang JH, Gore JC, et al. Amygdala and hippocampal volumes in adolescents and adults with bipolar disorder. Arch Gen Psychiatry. 2003;60(12):1201-8.
54. Chang K, Karchemskiy A, Barnea-Goraly N, Garrett A, Simeonova DI, Reiss A. Reduced amygdalar gray matter volume in familial pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2005;44(6):565-73.
55. Rosso IM, Cintron CM, Steingard RJ, Renshaw PF, Young AD, Yurgelun-Todd DA. Amygdala and hippocampus volumes in pediatric major depression. Biol Psychiatry. 2005;57(1):21-6.
56. Dickstein DP, Milham MP, Nugent AC, Drevets WC, Charney DS, Pine DS, et al. Frontotemporal alterations in pediatric bipolar disorder: results of a voxel-based morphometry study. Arch Gen Psychiatry. 2005;62(7):734-41.
57. Berretta S, Pantazopoulos H, Lange N. Neuron numbers and volume of the amygdala in subjects diagnosed with bipolar disorder or schizophrenia. Biol Psychiatry. 2007;62(8):884-93.
58. Bezchlibnyk YB, Sun X, Wang JF, MacQueen GM, McEwen BS, Young LT. Neuron somal size is decreased in the lateral amygdalar nucleus of subjects with bipolar disorder. J Psychiatry Neurosci. 2007;32(3):203-10.
59. Shin AC, Zheng H, Berthoud HR. An expanded view of energy homeostasis: neural integration of metabolic, cognitive, and emotional drives to eat. Physiol Behav. 2009;97(5):572-80.
60. Stoeckel LE, Kim J, Weller RE, Cox JE, Cook EW III, Horwitz B. Effective connectivity of a reward network in obese women. Brain Res Bull. 2009;79(6):388-95.
61. Millan MJ, Agid Y, Brune M, Bullmore ET, Carter CS, Clayton NS, et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov. 2012;11(2):141-68.
62. Bora E, Yucel M, Pantelis C. Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. J Affect Disord. 2009;113(1-2):1-20.
63. Mann-Wrobel MC, Carreno JT, Dickinson D. Meta-analysis of neuropsychological functioning in euthymic bipolar disorder: an update and investigation of moderator variables. Bipolar Disord. 2011;13(4):334-42.
64. Cohen RA. Obesity-associated cognitive decline: excess weight affects more than the waistline. Neuroepidemiology. 2010;34(4):230-1.
65. Sellbom KS, Gunstad J. Cognitive function and decline in obesity. J Alzheimers Dis. 2012;30(Suppl 2):S89-95.
66. McElroy SL, Keck PE Jr. Obesity in bipolar disorder: an overview. Curr Psychiatry Rep. 2012;14(6):650-8.
67. Krishnan KR. Psychiatric and medical comorbidities of bipolar disorder. Psychosom Med. 2005;67(1):1-8.
68. Klinitzke G, Steinig J, Bluher M, Kersting A, Wagner B. Obesity and suicide risk in adults - a systematic review. J Affect Disord. 2013;145(3):277-84.
69. Fernandes BS, Gama CS, Walz JC, Cereser KM, Fries GR, Colpo G, et al. Increased neurotrophin-3 in drug-free subjects with bipolar disorder during manic and depressive episodes. J Psychiatr Res. 2010;44(9):561-5.
70. Cunha AB, Frey BN, Andreazza AC, Goi JD, Rosa AR, Goncalves CA, et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett. 2006;398(3):215-9.
71. de Oliveira GS, Cereser KM, Fernandes BS, Kauer-Sant'Anna M, Fries GR, Stertz L, et al. Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients. J Psychiatr Res. 2009;43(14):1171-4.
72. Grande I, Magalhaes PV, Chendo I, Stertz L, Fries GR, Cereser KM, et al. Val66Met polymorphism and serum brain-derived neurotrophic factor in bipolar disorder: an open-label trial. Acta Psychiatr Scand. 2013;1-8 [Epub ahead of print]. doi: 10.1111/acps.12192.
73. Fan J, Sklar P. Genetics of bipolar disorder: focus on BDNF Val66Met polymorphism. Novartis Found Symp. 2008;289:60-72.
74. Unger TJ, Calderon GA, Bradley LC, Sena-Esteves M, Rios M. Selective deletion of Bdnf in the ventromedial and dorsomedial hypothalamus of adult mice results in hyperphagic behavior and obesity. J Neurosci. 2007;27(52):14265-74.
75. Shugart YY, Chen L, Day IN, Lewis SJ, Timpson NJ, Yuan W, et al. Two British women studies replicated the association between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) and BMI. Eur J Hum Genet. 2009;17(8):1050-5.
76. Rothman SM, Griffioen KJ, Wan R, Mattson MP. Brain-derived neurotrophic factor as a regulator of systemic and brain energy metabolism and cardiovascular health. Ann N Y Acad Sci. 2012;1264(1):49-63.
77. Herieka M, Erridge C. High-fat meal induced postprandial inflammation. Mol Nutr Food Res. 2013 [Epub ahead of print]. doi: 10.1002/mnfr.201300104.
78. Bray GA. Obesity: the disease. J Med Chem. 2006;49(14):4001-7.
79. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65(9):732-41.
80. Dantzer R. Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur J Pharmacol. 2004;500(1-3):399-411.
81. Munkholm K, Brauner JV, Kessing LV, Vinberg M. Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. J Psychiatr Res. 2013;47(9):1119-33.
82. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(4):952-5.
83. Gildengers A, Tatsuoka C, Bialko C, Cassidy KA, Al Jurdi RK, Gyulai L, et al. Correlates of treatment response in depressed older adults with bipolar disorder. J Geriatr Psychiatry Neurol. 2012;25(1):37-42.
84. Bowden CL, Calabrese JR, Ketter TA, Sachs GS, White RL, Thompson TR. Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder. Am J Psychiatry. 2006;163(7):1199-201.
85. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35(3):804-17.
86. Maes M, Kubera M, Obuchowiczwa E, Goehler L, Brzeszcz J. Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuro Endocrinol Lett. 2011;32(1):7-24.
87. Stertz L, Magalhaes PV, Kapczinski F. Is bipolar disorder an inflammatory condition? The relevance of microglial activation. Curr Opin Psychiatry. 2013;26(1):19-26.
88. Bazan NG. Lipid signaling in neural plasticity, brain repair, and neuroprotection. Mol Neurobiol. 2005;32(1):89-103.
89. Odebrecht VH, Vargas Nunes SO, Pizzo de Castro M, Cristina BC, Sabbatini BD, Kaminami MH, et al. Oxidative stress and lowered total antioxidant status are associated with a history of suicide attempts. J Affect Disord. 2013;150(3):923-30.
90. Wang JF, Shao L, Sun X, Young LT. Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord. 2009;11(5):523-9.
91. Kato T. The role of mitochondrial dysfunction in bipolar disorder. Drug News Perspect. 2006;19(10):597-602.
92. Kato T. Molecular genetics of bipolar disorder and depression. Psychiatry Clin Neurosci. 2007;61(1):3-19.
93. Kato T. Mitochondrial dysfunction as the molecular basis of bipolar disorder: therapeutic implications. CNS Drugs. 2007;21(1):1-11.
94. Lenaz G, Fato R, Formiggini G, Genova ML. The role of Coenzyme Q in mitochondrial electron transport. Mitochondrion. 2007;7(Suppl):S8-33.
95. Saretzki G, Von ZT. Replicative aging, telomeres, and oxidative stress. Ann N Y Acad Sci. 2002;959:24-9.
96. Elvsashagen T, Vera E, Boen E, Bratlie J, Andreassen OA, Josefsen D, et al. The load of short telomeres is increased and associated with lifetime number of depressive episodes in bipolar II disorder. J Affect Disord. 2011;135(1-3):43-50.
97. Medina-Gomez G. Mitochondria and endocrine function of adipose tissue. Best Pract Res Clin Endocrinol Metab. 2012;26(6):791-804.
98. Bondia-Pons I, Ryan L, Martinez JA. Oxidative stress and inflammation interactions in human obesity. J Physiol Biochem. 2012;68(4):701-11.
99. Cui Y, Gao YT, Cai Q, Qu S, Cai H, Li HL, et al. Associations of leukocyte telomere length with body anthropometric indices and weight change in chinese women. Obesity (Silver Spring). 2013;1-7 [Epub ahead of print]. doi: 10.1002/oby.20321.
100. Kim S, Parks CG, DeRoo LA, Chen H, Taylor JA, Cawthon RM, et al. Obesity and weight gain in adulthood and telomere length. Cancer Epidemiol Biomarkers Prev. 2009;18(3):816-20.
101. McGinty EE, Zhang Y, Guallar E, Ford DE, Steinwachs D, Dixon LB, et al. Cancer incidence in a sample of Maryland residents with serious mental illness. Psychiatr Serv. 2012;63(7):714-7.
102. Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R. The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(3):702-21.
103. Myint AM, Kim YK, Verkerk R, Scharpe S, Steinbusch H, Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord. 2007;98(1-2):143-51.
104. Muller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry. 2007;12(11):988-1000.
105. Moron JA, Zakharova I, Ferrer JV, Merrill GA, Hope B, Lafer EM, et al. Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. J Neurosci. 2003;23(24):8480-8.
106. Berridge KC, Ho CY, Richard JM, Difeliceantonio AG. The tempted brain eats: pleasure and desire circuits in obesity and eating disorders. Brain Res. 2010;2(1350):43-64.
107. McIntyre RS, McElroy SL, Konarski JZ, Soczynska JK, Bottas A, Castel S, et al. Substance use disorders and overweight/obesity in bipolar I disorder: preliminary evidence for competing addictions. J Clin Psychiatry. 2007;68(9):1352-7.
108. Musselman DL, Betan E, Larsen H, Phillips LS. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry. 2003;54(3):317-29.
109. Thaler JP, Choi SJ, Schwartz MW, Wisse BE. Hypothalamic inflammation and energy homeostasis: resolving the paradox. Front Neuroendocrinol. 2010;31(1):79-84.
110. Nieto-Vazquez I, Fernandez-Veledo S, Kramer DK, Vila-Bedmar R, Garcia-Guerra L, Lorenzo M. Insulin resistance associated to obesity: the link TNF-alpha. Arch Physiol Biochem. 2008;114(3):183-94.
111. Venters HD, Dantzer R, Kelley KW. A new concept in neurodegeneration: TNFalpha is a silencer of survival signals. Trends Neurosci. 2000;23(4):175-80.
112. Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord. 2003;27(Suppl 3):S53-5.
113. Boghossian S, Lemmon K, Park M, York DA. High-fat diets induce a rapid loss of the insulin anorectic response in the amygdala. Am J Physiol Regul Integr Comp Physiol. 2009;297(5):R1302-11.
114. McIntyre RS, Soczynska JK, Woldeyohannes HO, Miranda A, Vaccarino A, Macqueen G, et al. A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder. Bipolar Disord. 2012;14(7):697-706.
115. Bornstein SR, Schuppenies A, Wong ML, Licinio J. Approaching the shared biology of obesity and depression: the stress axis as the locus of gene-environment interactions. Mol Psychiatry. 2006;11(10):892-902.
116. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409(6818):307-12.
117. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol. 2005;174(9):5789-95.
118. Weber-Hamann B, Kratzsch J, Kopf D, Lederbogen F, Gilles M, Heuser I, et al. Resistin and adiponectin in major depression: the association with free cortisol and effects of antidepressant treatment. J Psychiatr Res. 2007;41(3-4):344-50.
119. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999;100(25):2473-6.
120. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood. 2000;96(5):1723-32.
121. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med. 2002;8(7):731-7.
122. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab. 2002;13(2):84-9.
123. Farooqi IS, Bullmore E, Keogh J, Gillard J, O'Rahilly S, Fletcher PC. Leptin regulates striatal regions and human eating behavior. Science. 2007;317(5843):1355.
124. Rosenbaum M, Murphy EM, Heymsfield SB, Matthews DE, Leibel RL. Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thyroid hormones. J Clin Endocrinol Metab. 2002;87(5):2391-4.
125. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature. 1998;394(6696):897-901.
126. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature. 1998;395(6704):763-70.
127. Lu XY, Kim CS, Frazer A, Zhang W. Leptin: a potential novel antidepressant. Proc Natl Acad Sci USA. 2006;103(5):1593-8.
128. Eikelis N, Esler M, Barton D, Dawood T, Wiesner G, Lambert G. Reduced brain leptin in patients with major depressive disorder and in suicide victims. Mol Psychiatry. 2006;11(9):800-1.
129. Yamada N, Katsuura G, Ochi Y, Ebihara K, Kusakabe T, Hosoda K, et al. Impaired CNS leptin action is implicated in depression associated with obesity. Endocrinology. 2011;152(7):2634-43.
130. Ceulemans S, De ZS, Heyrman L, Norrback KF, Nordin A, Nilsson LG, et al. Evidence for the involvement of the glucocorticoid receptor gene in bipolar disorder in an isolated northern Swedish population. Bipolar Disord. 2011;13(7-8):614-23.
131. Wang Q, Verweij EW, Krugers HJ, Joels M, Swaab DF, Lucassen PJ. Distribution of the glucocorticoid receptor in the human amygdala; changes in mood disorder patients. Brain Struct Funct. 2013;1-12 [Epub ahead of print]. doi: 10.1007/s00429-013-0589-4.
132. Kamali M, Saunders EF, Prossin AR, Brucksch CB, Harrington GJ, Langenecker SA, et al. Associations between suicide attempts and elevated bedtime salivary cortisol levels in bipolar disorder. J Affect Disord. 2012;136(3):350-8.
133. Lopresti AL, Drummond PD. Obesity and psychiatric disorders: commonalities in dysregulated biological pathways and their implications for treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2013;45:92-9.
134. McIntyre RS, Powell AM, Kaidanovich-Beilin O, Soczynska JK, Alsuwaidan M, Woldeyohannes HO, et al. The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders. Behav Brain Res. 2013;15(237):164-71.
135. Matikainen N, Bogl LH, Hakkarainen A, Lundbom J, Lundbom N, Kaprio J, et al. GLP-1 responses are heritable and blunted in acquired obesity with high liver fat and insulin resistance. Diabetes Care. 2013 [Epub ahead of print]. doi: 10.2337/dc13-1283.
136. Lucas K, Maes M. Role of the Toll Like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 Pathway. Mol Neurobiol. 2013;48(1):190-204.
137. O'Neil A, Sanna L, Redlich C, Sanderson K, Jacka F, Williams LJ, et al. The impact of statins on psychological wellbeing: a systematic review and meta-analysis. BMC Med. 2012;10:154.
138. Krag DN, Theon AP, Gan L. Hyperthermic enhancement of rhodamine 123 cytotoxicity in B16 mouse melanoma cells in vitro. Cancer Res. 1990;50(8):2385-9.
139. Maes M, Fisar Z, Medina M, Scapagnini G, Nowak G, Berk M. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates - Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology. 2012;20(3):127-50.
140. Stafford L, Berk M. The use of statins after a cardiac intervention is associated with reduced risk of subsequent depression: proof of concept for the inflammatory and oxidative hypotheses of depression? J Clin Psychiatry. 2011;72(9):1229-35.
141. Kip KE, Marroquin OC, Kelley DE, Johnson BD, Kelsey SF, Shaw LJ, et al. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. Circulation. 2004;109(6):706-13.
142. McIntyre RS, Soczynska JK, Liauw SS, Woldeyohannes HO, Brietzke E, Nathanson J, et al. The association between childhood adversity and components of metabolic syndrome in adults with mood disorders: results from the international mood disorders collaborative project. Int J Psychiatry Med. 2012;43(2):165-77.
143. van Reedt Dortland AK, Giltay EJ, van Veen T, Zitman FG, Penninx BW. Personality traits and childhood trauma as correlates of metabolic risk factors: the Netherlands Study of Depression and Anxiety (NESDA). Prog Neuropsychopharmacol Biol Psychiatry. 2012;36(1):85-91.
144. Danese A, Tan M. Childhood maltreatment and obesity: systematic review and meta-analysis. Mol Psychiatry. 2013;1-11. doi: 10.1038/mp.2013.54.